ZYDUSLIFE

The Delhi High Court has allowed

to manufacture and sell a biosimilar version of Bristol Myers Squibb's cancer drug Nivolumab, priced nearly 70% lower, citing public interest. Justices C Hari Shankar and Om Prakash Shukla overruled a previous ruling and directed Zydus to maintain sales records until the patent expires on May 2, 2026.